A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab, mycophenolate, ciclosporin and corticosteroids) in renal transplantation.

Trial Profile

A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab, mycophenolate, ciclosporin and corticosteroids) in renal transplantation.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2015

At a glance

  • Drugs Sirolimus (Primary) ; Ciclosporin; Corticosteroids; Daclizumab; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top